Stem-cell therapy for Parkinson's shows 'strong promise' in relieving symptoms
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have announced progress on that front — they have developed a new therapy that uses stem cells to treat advanced Parkinson's.
In the phase 1 trial, the researchers used donated stem cells (taken from early-stage embryos) to create nerve cells (neurons) and transplanted them into the brains of 12 Parkinson's patients, according to a press release from MSK.
New Drug For Parkinson's Shown To Be Effective In Clinical Trials: 'Very Encouraged'
Once the cells are injected, they produce dopamine, a hormone in the brain that helps with movement and coordination.
(One of the hallmarks of Parkinson's is low levels of dopamine, which causes the typical symptoms of tremors, stiffness, balance issues and difficulty walking.)
Read On The Fox News App
After 18 months, the injected cells had "taken hold in the brain with no serious side effects," the researchers reported.
Based on the MDS-UPDRS — a ratings scale for symptoms developed by the International Parkinson and Movement Disorder Society — the participants experienced "noticeable improvements," especially the group that received a higher dose.
"Neurologists say things usually get a little bit worse every year with this disease, meaning the score goes up by a few points," study co-author Lorenz Studer, MD, director of MSK's Center for Stem Cell Biology, said in the press release.
"In our study, not only did the score not get worse, it dropped by more than 20 points in the high-dose group."
On average, patients in the high-dose group reported 2.7 hours of additional "on time" — indicating periods of normal functioning with minimal symptoms — "a result that could be quite meaningful for their everyday life," Studer noted.
Given the success of the phase 1 trial, the U.S. Food and Drug Administration (FDA) has granted approval for the researchers to go straight to a phase 3 clinical trial in a much larger patient group — around 100 people — which will take place in the first half of 2025.
The findings were published in the journal Nature.
Parkinson's Cases Could Double Globally By 2050, Study Reveals
"The study showed that developing specific nerve cells from human embryonic stem cells in the lab, then injecting them in the brain of people with Parkinson's disease, is safe and holds significant promise as a possible future treatment," lead study author Viviane Tabar, MD, chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center in New York City, told Fox News Digital.
"The findings were rewarding, as this work is more than a dozen years in the making."
Dr. Mary Ann Picone, medical director of the MS Center at Holy Name Medical Center in Teaneck, New Jersey, said that cells for the treatment of Parkinson's disease could offer potential for not only slowing disability, but also stopping progression and bringing about improvement in motor function.
"Although there is risk involved in the immune suppression necessary before the stem cell implantation and the procedure itself, it would be a major step forward in replacing the dopaminergic neurons lost in the disease," Picone, who was not involved in the study, told Fox News Digital.
Levodopa, currently the first-line treatment for Parkinson's, is limited in that patients need greater dosage amounts as time goes on, according to Picone — "and regulating off and on periods of either stiffness or dyskinesias (uncontrolled muscle movements) becomes more difficult."
Dr. Ann Murray, director of movement disorders at WVU Rockefeller Neuroscience Institute in West Virginia, referred to the study as "unbelievably exciting" for Parkinson's patients.
"Although the goal of this particular research project was to ensure safety, getting that significant clinical improvement in the UPDRS is absolutely groundbreaking," Murray told Fox News Digital. (She also was not involved in the study.)
Click Here To Sign Up For Our Health Newsletter
"This is just the first step in getting this type of therapy approved for patients suffering from Parkinson's disease, but this is an amazing first step for the potential benefits of stem cell brain therapy."
There were some limitations associated with the study, Tabar noted.
"This is a small study designed to show safety — it is critical to conduct a larger, well-controlled study to prove that the treatment indeed works, otherwise referred to as a Phase 3 'efficacy' study," she said.
These early findings, however, are "suggestive of a strong promise."
"I think we can finally say that stem cells, when derived and differentiated properly, hold great promise to repair the brain in Parkinson's and potentially in other conditions someday," Tabar said.
For more Health articles, visit www.foxnews.com/health
The cell therapy was developed at MSK and was licensed to BlueRock Therapeutics in Massachusetts, which funded the study.Original article source: Stem-cell therapy for Parkinson's shows 'strong promise' in relieving symptoms
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
12 minutes ago
- Business Upturn
What killed Ozzy Osbourne? Death certificate confirms cause
By Aman Shukla Published on August 5, 2025, 21:38 IST Ozzy Osbourne, the legendary frontman of Black Sabbath and one of the most iconic figures in rock history, passed away on July 22, 2025, at the age of 76. Known worldwide as the Prince of Darkness , Ozzy's death marks the end of an era for heavy metal and rock fans across the globe. Official Cause of Death Revealed According to his death certificate, Ozzy died from an out-of-hospital cardiac arrest caused by an acute myocardial infarction — a medical term for a heart attack. Additional contributing factors included coronary artery disease and Parkinson's disease with autonomic dysfunction, a condition that affects involuntary bodily functions like heart rate and blood pressure. His death certificate also proudly noted his occupation as 'Songwriter, Performer and Rock Legend,' reflecting his immense impact on the music world. A Long Battle With Health Issues Ozzy had been battling multiple serious health problems for years. He was first diagnosed with Parkinson's disease in the early 2000s, though the diagnosis was publicly confirmed only in 2020. The condition affected his balance, mobility, and speech, but he continued to remain active and creative despite it. His health further declined after a quad bike accident in 2003, which left him with severe injuries, followed by a bad fall in 2019 that worsened his spinal condition. Multiple surgeries and infections over the years took a heavy toll on his body. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Wire
a day ago
- Business Wire
National Clinical Reimbursement Leader Kelly Roberts Joins CoreCare to Lead AI-Powered Transformation
NEW YORK--(BUSINESS WIRE)-- CoreCare, the leading AI-powered workflow platform for post-acute and long-term care providers, announced today that Kelly Roberts has joined the company as Senior Vice President of MDS Innovation & Transformation. Kelly Roberts brings more than two decades of clinical reimbursement leadership to CoreCare, most recently serving as Senior VP of Clinical Reimbursement at Creative Solutions in Healthcare, the nation's fifth largest skilled nursing operator. Roberts brings more than two decades of clinical reimbursement leadership to CoreCare, most recently serving as Senior Vice President of Clinical Reimbursement at Creative Solutions in Healthcare, the nation's fifth largest skilled nursing operator. There, she oversaw reimbursement across more than 160 facilities, led systemwide MDS strategies, and founded one of the largest MDS leadership summits in the country. At CoreCare, Roberts will lead the development of next-generation AI solutions designed to improve reimbursement accuracy, ensure compliance, and help skilled nursing facilities (SNFs) thrive in an increasingly complex environment. Her appointment comes as CoreCare's revenue has more than doubled year over year, with its platform now powering intake, eligibility, and billing automation. 'Kelly's leadership has always been rooted in collaboration,' said Gary Blake, President and CEO of Creative Solutions in Healthcare. 'She worked hand in hand with our clinical compliance, operations teams, and leaders across every department to strengthen our systems and elevate how we serve. We celebrate her taking this next step, knowing she will bring that same spirit of partnership and innovation to the industry through her work at CoreCare.' 'I'm excited to be a part of the CoreCare team to lead this new era of AI-driven MDS technology and the possibilities it brings to improve accuracy, efficiency, and outcomes. Our goal is simple: support staff where they need it most - streamlining clinical reimbursement so they can focus on resident care,' said Roberts. 'Kelly is one of the most respected minds and leaders in skilled nursing reimbursement,' said Dennis Antonelos, CEO and Co-founder of CoreCare. 'She's lived the challenges operators face and knows what excellence looks like from the inside. With her leadership, we're helping providers transform their operations with AI, capture more accurate reimbursement, and stay financially strong in today's high-stakes environment.' About CoreCare CoreCare is the leading AI-powered workflow platform built specifically for post-acute and long-term care providers. Trusted by thousands of skilled nursing facilities nationwide, CoreCare's platform replaces spreadsheets, manual reviews, and disconnected portals with technology that enables expert-level decisions and teamwork at every step of the revenue cycle. Backed by Y Combinator and leading health tech investors, CoreCare is building the infrastructure for AI-powered healthcare operations. To learn more about CoreCare, visit and connect with us on LinkedIn.
Newsweek
4 days ago
- Newsweek
A Doctor's Plea From a Nation Asleep on Brain Disease
Advocates for ideas and draws conclusions based on the interpretation of facts and data. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. As a physician who once treated pain, I now endure the unimaginable. Amyotrophic lateral sclerosis (ALS) has left me quadriplegic, dependent on a tracheostomy to breathe and a feeding tube to eat. Diagnosed at 35, my career ended abruptly. My family's story reveals the scale of the coming storm—my father battles Alzheimer's, my uncle succumbed to Parkinson's, and my grandmother to Lewy body dementia. We are not outliers; we represent a silent epidemic. Neurodegenerative diseases are surging, yet our nation slumbers, unaware of the devastation ahead. The public's complacency is by design, built on a statistical illusion. ALS, fatal since 1869, exemplifies this peril. With a median survival of 2-3 years, it strikes about 1 in 300 people in their lifetime, which predicts that over 1 million people now alive in the U.S. will succumb to ALS. Yet, under federal law, it is labeled "rare" because that definition is based on prevalence—a static snapshot of how many people are living with a disease at one time. Because ALS kills its victims so quickly, the number of living patients stays below the 200,000-person "rare" threshold. Its very lethality ensures it is never treated like the mainstream public health crisis it is. This paradox obscures a terrifying forecast: a projected 69 percent global increase in ALS cases by 2040. This illusion of rarity perpetuates a deadly inaction that extends to all brain diseases. Alzheimer's already affects over 7 million Americans and is projected to strike nearly 13 million by 2050, costing our economy $384 billion in 2025—and projected to nearly $1 trillion annually by mid-century. Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Getty Images The failure to confront this crisis stems from a Tale of Two Agencies within the Food and Drug Administration (FDA). In 2017, Congress established the Oncology Center of Excellence (OCE), a dynamic hub that has revolutionized cancer treatment, accounting for 85 percent of all accelerated approvals in the last decade. This success is the result of focused will and resources; National Institutes of Health (NIH) funding for cancer has topped $7.2 billion, compared to $2.8 billion for neuroscience. Neurology has no such center. Lacking an institutional home, it is fragmented, slow, and characterized by a risk aversion unthinkable in oncology. This disparity persists because of the tragic nature of these diseases. In the 1980s, ACT UP activists staged "die-ins" to force a reluctant government to fight AIDS. Patients with ALS, Huntington's, or Alzheimer's cannot mount a similar protest—we are physically silenced and immobilized, unable to "seize the FDA." This vulnerability places a unique moral obligation on our leaders to act proactively on behalf of the voiceless. The new FDA leadership now arrives with bold promises of change, posing a question that haunts everyone touched by an untreatable neurological disease: Will this time be different? Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. vows to "sweep away barriers" and to "figure out new ways ... of accelerating approvals for drugs and treatments that treat rare diseases." FDA Commissioner Marty Makary has several times asked why it takes 10 years for a drug to get to market and proposes a "conditional approval" pathway based on a "plausible mechanism." Center for Biologics Evaluation and Research (CBER) Director Vinay Prasad promised to "take action at the first sign of promise for rare diseases." For the ALS community, these words are now a crisis of credibility. In a disease that has a median survival of 2-3 years, we are asking for regulatory flexibility for a treatment that began its Phase 1 trial in 2011 and was granted FDA Fast Track designation in 2014. As a petitioner on the July 3 citizens' petition for a stem cell therapy known as NurOwn, my community has presented the FDA with a clear test. Ultimately, we are seeking accelerated approval based on new, unprecedented survival data from an expanded access program—data that exceeds the extension of survival of many approved cancer therapies. But the initial request is simpler: invite the sponsor to resubmit its application for a full review. Ours is a request for due process to give a voice to the voiceless—the lowest possible bar for the Trump administration to demonstrate its promised flexibility. A clear, bipartisan solution has already failed once. The Neuroscience Center of Excellence Act, introduced in 2021 to replicate oncology's success for brain disease, stalled in committee. It is time for our leaders to find the political will that has been so catastrophically absent. Congress must immediately revive and pass the Neuroscience Center of Excellence Act. The FDA, in turn, must match its leaders' promises with action by granting our petition a review. The science is poised for breakthroughs, but it is being shackled by a broken system. For those of us on a deadline, this is not a policy debate. It is a death sentence. Awaken now, before this silent storm engulfs us all. The voiceless can't wait. Dr. Shahriar Minokadeh, a former anesthesiologist trained at Johns Hopkins and pain management at UC San Diego, types via an eye-gaze device. The views expressed in this article are the writer's own.
